BHVN 39.4 (+1.03%)
VGG111961055BiotechnologyBiotechnology

Biohaven Pharmaceutical Holding (BHVN) Stock Highlights

39.4 | +1.03%
2024-09-19 01:30:29
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others.

Statistics

Range Today
38.51 40.24
Volume Today 1.1M
Range 1 Year
16.45 62.21
Volume 1 Year 298.53M
Range 3 Year
5.54 151.51
Volume 3 Year 822.65M
Range 10 Year
5.54 151.51
Volume 10 Year 1.47B

Highlights

Market Capitalization 3.44B (mid)
Floating Shares 80.19M
Current Price 39.4
Price To Earnings -3.89
Price To Book 9.36
Earnings Per Share -9.3
Payout Ratio 0%

Performance

Latest +1.03%
1 Month +2.55%
3 Months +18.6%
6 Months -32.37%
1 Year +108.91%
3 Years -70.08%
5 Years -17.14%
10 Years +97%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.